USPSTF Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication for Adults
| Age Range | Recommendation |
|---|---|
| Adults younger than 50 years | The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults younger than 50 years. |
| Adults age 50–59 years with a ≥10% 10-year CVD risk | The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults age 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. |
| Adults age 60–69 years with a ≥10% 10-year CVD risk | The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults age 60 to 69 years who have a 10% or greater 10-year CVD risk should be an individual one. Persons who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years are more likely to benefit. Persons who place a higher value on the potential benefits than the potential harms may choose to initiate low-dose aspirin. |
| Adults age 70 years or older | The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults age 70 years or older. |
Note: This recommendation applies to adults who are at increased CVD risk and at average risk for CRC. Persons who are at increased CVD risk and are known to be at increased risk for CRC (e.g., persons with a family or personal history of CRC or familial adenomatous polyposis) should consult their healthcare provider.
CRC, colorectal cancer; CVD, cardiovascular disease; USPSTF, U.S. Preventive Services Task Force.